Cara Therapeutics (CARA) Short Interest Ratio & Short Volume

Short interest is the volume of Cara Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 2,610,000 shares of CARA short. 5.62% of Cara Therapeutics' shares are currently sold short. Learn More on Cara Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CARA shares currently have a short interest ratio of 4.0. Learn More on Cara Therapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cara Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.62% of Cara Therapeutics' floating shares are currently sold short.

Cara Therapeutics currently has issued a total of 54,670,000 shares. Some of Cara Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cara Therapeutics currently has a public float of 46,470,000 shares.

5.62% of Cara Therapeutics' shares are currently sold short. Here is how the short interest of companies compare to Cara Therapeutics: Unicycive Therapeutics, Inc. (2.13%), NextCure, Inc. (0.53%), Lexaria Bioscience Corp. (2.29%), Eyenovia, Inc. (12.11%), Sensei Biotherapeutics, Inc. (0.37%), Bolt Biotherapeutics, Inc. (8.80%), VYNE Therapeutics Inc. (0.68%), Immuneering Co. (15.37%), Xilio Therapeutics, Inc. (5.24%), Rockwell Medical, Inc. (2.13%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks.

Short selling CARA is an investing strategy that aims to generate trading profit from Cara Therapeutics as its price is falling. CARA shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Cara Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CARA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CARA, twice per month. The most recent reporting period available is April, 30 2024.